Brokerages expect that Ritter Pharmaceuticals Inc (NASDAQ:RTTR) will report ($0.04) earnings per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Ritter Pharmaceuticals’ earnings. Ritter Pharmaceuticals reported earnings per share of ($0.74) during the same quarter last year, which would indicate a positive year-over-year growth rate of 94.6%. The firm is expected to issue its next quarterly earnings results on Monday, February 26th.

On average, analysts expect that Ritter Pharmaceuticals will report full-year earnings of ($0.35) per share for the current year. For the next fiscal year, analysts forecast that the company will report earnings of ($0.40) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that follow Ritter Pharmaceuticals.

A number of brokerages have weighed in on RTTR. ValuEngine upgraded shares of Ritter Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Zacks Investment Research downgraded shares of Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, December 26th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. Ritter Pharmaceuticals currently has an average rating of “Hold” and an average price target of $2.10.

Shares of Ritter Pharmaceuticals (RTTR) traded down $0.01 during trading on Thursday, hitting $0.30. 344,811 shares of the company’s stock were exchanged, compared to its average volume of 372,640. The firm has a market capitalization of $14.80 and a P/E ratio of -0.26. Ritter Pharmaceuticals has a 1-year low of $0.27 and a 1-year high of $3.39.

A hedge fund recently bought a new stake in Ritter Pharmaceuticals stock. Susquehanna International Group LLP bought a new position in shares of Ritter Pharmaceuticals Inc (NASDAQ:RTTR) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 2,222,522 shares of the biotechnology company’s stock, valued at approximately $778,000. Susquehanna International Group LLP owned approximately 4.49% of Ritter Pharmaceuticals as of its most recent SEC filing. Institutional investors own 33.61% of the company’s stock.

WARNING: This news story was originally published by Daily Political and is owned by of Daily Political. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Get a free copy of the Zacks research report on Ritter Pharmaceuticals (RTTR)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with's FREE daily email newsletter.